Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Lafora Disease Is an Inherited Metabolic Cardiomyopathy

  • Villalba Orero, María
  • Gentzane Sánchez-Elexpuru, Gentzane
  • López-Olañeta, Marina
  • Campuzano, Oscar
  • Bello-Arroyo, Elisabet
  • García-Pavía, Pablo
  • Serratosa, José
  • Brugada, Ramón
  • Sánchez, Marina
  • Lara-Pezzi, Enrique
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Differential patterns of subcortical activity evoked by Glial GLT-1 blockade in prelimbic and infralimbic cortex: Relationship to antidepressant-like effects in rats

  • Gasull-Camos, Julia
  • Soto Montenegro, Mª Luisa
  • Casquero-Veiga, Marta
  • Desco Menéndez, Manuel
  • Artigas, Francesc
  • Castañe, Anna
Background: Glutamatergic neurotransmission has emerged as a novel target in antidepressant drug development, with a critical role of the ventral anterior cingulate cortex. We recently reported that blockade of the astrocytic glutamate transporter GLT-1 with dihydrokainic acid in infralimbic cortex (rodent equivalent of ventral anterior cingulate cortex), but not in the adjacent prelimbic cortex, evoked robust antidepressant-like effects through alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation and increased serotonin release. Methods: 2-deoxy-2-[F-18]-fluoro-D-glucose-positron emission tomography and computed tomography in 36 male Wistar rats microinfused bilaterally in prelimbic cortex or infralimbic cortex with dihydrokainic acid or vehicle. Results: Dihydrokainic acid microinfusion in infralimbic cortex and prelimbic cortex evoked dramatically different regional patterns of subcortical activity. In infralimbic cortex, dihydrokainic acid selectively affected midbrain areas, whereas in prelimbic cortex it affected the basal ganglia, the thalamus, and both superior and inferior colliculi. Conclusions: These results highlight the differential connectivity of infralimbic and prelimbic cortex with subcortical brain regions and support the involvement of infralimbic cortex-midbrain pathway in the antidepressant-like effects of dihydrokainic acid., This work was supported by Spanish Ministry of Economy and Competitiveness grants (SAF2012-35183, SAF2015-68346, ISCIII-FIS PI14/00860 and CPII14/00005, and BES2013-063241 J.GC.) cofinanced by European Regional Development Fund, Generalitat de Catalunya (2014-SGR798), Comunidad de Madrid (BRADE-CM S2013/ICE-2958), Mapfre foundation, Alicia Koplowitz Foundation (FAK16/01), and Centro de Investigación Biomédica en Red de Salud Mental.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease

  • Sevilla, Teresa
  • Lupo, Vincenzo
  • Martínez-Rubio, Dolores
  • Sancho, Paula
  • Sivera, Rafael
  • Chumillas, María J.
  • García-Romero, Mar
  • Pascual-Pascual, Samuel I.
  • Muelas, Nuria
  • Dopazo, Joaquín
  • Vílchez, Juan J.
  • Palau, Francesc
  • Espinós-Armero, Carmen Ángeles
[EN] Charcot-Marie-Tooth disease (CMT) is a complex disorder with wide genetic heterogeneity. Here we present a new axonal Charcot-Marie-Tooth disease form, associated with the gene microrchidia family CW-type zinc finger 2 (MORC2). Whole-exome sequencing in a family with autosomal dominant segregation identified the novel MORC2 p. R190W change in four patients. Further mutational screening in our axonal Charcot-Marie-Tooth disease clinical series detected two additional sporadic cases, one patient who also carried the same MORC2 p. R190W mutation and another patient that harboured a MORC2 p. S25L mutation. Genetic and in silico studies strongly supported the pathogenicity of these sequence variants. The phenotype was variable and included patients with congenital or infantile onset, as well as others whose symptoms started in the second decade. The patients with early onset developed a spinal muscular atrophy-like picture, whereas in the later onset cases, the initial symptoms were cramps, distal weakness and sensory impairment. Weakness and atrophy progressed in a random and asymmetric fashion and involved limb girdle muscles, leading to a severe incapacity in adulthood. Sensory loss was always prominent and proportional to disease severity. Electrophysiological studies were consistent with an asymmetric axonal motor and sensory neuropathy, while fasciculations and myokymia were recorded rather frequently by needle electromyography. Sural nerve biopsy revealed pronounced multifocal depletion of myelinated fibres with some regenerative clusters and occasional small onion bulbs. Morc2 is expressed in both axons and Schwann cells of mouse peripheral nerve. Different roles in biological processes have been described for MORC2. As the silencing of Charcot-Marie-Tooth disease genes have been associated with DNA damage response, it is tempting to speculate that a deregulation of this pathway may be linked to the axonal degeneration observed in MORC2 neuropathy, thus adding a new pathogenic mechanism to the long list of causes of Charcot-Marie-Tooth disease., This collaborative joint project is awarded by IRDiRC and funded by the Instituto de Salud Carlos III (ISCIII) - Subdireccion General de Evaluacion y Fomento de la Investigacion within the framework of the National R+D+I Plan (IR11/TREAT-CMT to T.S., S.I.P.P., F.P. and C.E.; PI12/00453 to C.E.; and PI12/0946 to T.S.), co-funded with FEDER funds. Additional support was provided by the Ramon Areces Foundation and by the ISCIII and the Centro de Investigacion Principe Felipe (CPII14/00002) to C.E.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Assessment of Targeted Next-Generation Sequencing as a Tool for the Diagnosis of Charcot-Marie-Tooth Disease and Hereditary Motor Neuropathy

  • Lupo, Vincenzo
  • Sancho, Paula
  • Tello, Cristina
  • García-Romero, Mar
  • Villarreal, Liliana
  • Alberti, Antonia
  • Sivera, Rafael
  • Pascual-Pascual, Samuel I.
  • Márquez-Infante, Celedonio
  • Casasnovas, Carlos
  • Sevilla, Teresa
  • Espinós-Armero, Carmen Ángeles
  • García García, Francisco|||0000-0003-1488-2764
[EN] Charcot-Marie-Tooth disease is characterized by broad genetic heterogeneity with >50 known disease-associated genes. Mutations in some of these genes can cause a pure motor form of hereditary motor neuropathy, the genetics of which are poorly characterized. We designed a panel comprising 56 genes associated with Charcot-Marie-Tooth disease/hereditary motor neuropathy. We validated this diagnostic tool by first testing 11 patients with pathological mutations. A cohort of 33 affected subjects was selected for this study. The DNA382 c.352+1G>A mutation was detected in two cases; novel changes and/or variants with low frequency (<1%) were found in 12 cases. There were no candidate variants in 18 cases, and amplification failed for one sample. The DNAJB2 c.352+1G>A mutation was also detected in three additional families. On haplotype analysis, all of the patients from these five families shared the same haplotype; therefore, the DNAJ82 c.352+1G>A mutation may be a founder event. Our gene panel allowed us to perform a very rapid and cost-effective screening of genes involved in Charcot-Marie-Tooth disease/hereditary motor neuropathy. Our diagnostic strategy was robust in terms of both coverage and read depth for all of the genes and patient samples. These findings demonstrate the difficulty in achieving a definitive molecular diagnosis because of the complexity of interpreting new variants and the genetic heterogeneity that is associated with these neuropathies., Supported by grants IR11/TREAT-CMT (C.E., CC., CM.-I., S.I.P.-P.) and PI12/00453 (C.E.) from the Institute de Salud Carlos III (ISCII)-Subdireccion General de Evaluation y Fomento de la Investigacion within the framework of the National R + D + I Plan, cofunded by the European Regional Development Fund. This collaborative joint project was awarded by the International Rare Diseases Research Consortium. C.E. has a "Miguel Servet" contract funded by grant CPII14/00002 from the ISCII and the Centro de Investigacion Principe Felipe (CEPF). The Centro de Investigacion Biomedica en Red de Enfermedades Raras is an initiative of the ISCIII.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

The Drosophila junctophilin gene is functionally equivalent to its four mammalian counterparts and is a modifier of a Huntingtin poly-Q expansion and the Notch pathway

  • Calpena-Corpas, Eduardo
  • Lopez del Amo, V
  • Chakraborty M
  • Llamusi, B
  • Artero R
  • Espinos, Carmen
  • Galindo, Máximo Ibo|||0000-0001-8448-9760
[EN] Members of the Junctophilin (JPH) protein family have emerged as key actors in all excitable cells, with crucial implications for human pathophysiology. In mammals, this family consists of four members (JPH1-JPH4) that are differentially expressed throughout excitable cells. The analysis of knockout mice lacking JPH subtypes has demonstrated their essential contribution to physiological functions in skeletal and cardiac muscles and in neurons. Moreover, mutations in the human JPH2 gene are associated with hypertrophic and dilated cardiomyopathies; mutations in JPH3 are responsible for the neurodegenerative Huntington's disease-like-2 (HDL2), whereas JPH1 acts as a genetic modifier in Charcot-Marie-Tooth 2K peripheral neuropathy. Drosophila melanogaster has a single junctophilin (jp) gene, as is the case in all invertebrates, which might retain equivalent functions of the four homologous JPH genes present in mammalian genomes. Therefore, owing to the lack of putatively redundant genes, a jp Drosophila model could provide an excellent platform to model the Junctophilin-related diseases, to discover the ancestral functions of the JPH proteins and to reveal new pathways. By up-and downregulation of Jp in a tissue-specific manner in Drosophila, we show that altering its levels of expression produces a phenotypic spectrum characterized by muscular deficits, dilated cardiomyopathy and neuronal alterations. Importantly, our study has demonstrated that Jp modifies the neuronal degeneration in a Drosophila model of Huntington's disease, and it has allowed us to uncover an unsuspected functional relationship with the Notch pathway. Therefore, this Drosophila model has revealed new aspects of Junctophilin function that can be relevant for the disease mechanisms of their human counterparts., This work was supported by project grants from Association Francaise contre les Myopathies [AFM 18540 to M.I.G.], Instituto de Salud Carlos III (ISCIII) [PI12/000453 and PI15/000187 to C.E.], Generalitat Valenciana [PROMETEOII/2014/067 to R.A. as partner], and a collaborative grant from the International Rare Diseases Research Consortium (IRDiRC) and ISCIII [IR11/TREAT-CMT to M.I.G. (partner 12) and C.E. (partner 6)]. C.E. has a 'Miguel Servet' contract funded by the ISCIII and Centro de Investigacion Principe Felipe [CPII14/00002]; M.C. was the recipient of a Santiago Grisolia award from Generalitat Valenciana [GrisoliaP/2013/A/044].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Characterization of molecular mechanisms underlying the axonal Charcot-Marie-Tooth neuropathy caused by MORC2 mutations

  • Sancho, Paula
  • Bartesaghi, Luca
  • Miossec, Olivia
  • García-García, Francisco
  • Ramírez-Jiménez, Laura
  • Siddell, Anna
  • Ajkesson, Elisabet
  • Hedlund, Eva
  • Lassuthova, Petra
  • Pascual-Pascual, Samuel I.
  • Sevilla, Teresa
  • Kennerson, Marina
  • Lupo, Vincenzo
  • Chrast, Roman
  • Espinós-Armero, Carmen Ángeles
[EN] Mutations in MORC2 lead to an axonal form of Charcot-Marie-Tooth (CMT) neuropathy type 2Z. To date, 31 families have been described with mutations in MORC2, indicating that this gene is frequently involved in axonal CMT cases. While the genetic data clearly establish the causative role of MORC2 in CMT2Z, the impact of its mutations on neuronal biology and their phenotypic consequences in patients remains to be clarified. We show that the full-length form of MORC2 is highly expressed in both embryonic and adult human neural tissues and that Morc2 expression is dynamically regulated in both the developing and the maturing murine nervous system. To determine the effect of the most common MORC2 mutations, p.S87L and p.R252W, we used several in vitro cell culture paradigms. Both mutations induced transcriptional changes in patient-derived fibroblasts and when expressed in rodent sensory neurons. These changes were more pronounced and accompanied by abnormal axonal morphology, in neurons expressing the MORC2 p.S87L mutation, which is associated with a more severe clinical phenotype. These data provide insight into the neuronal specificity of the mutated MORC2-mediated phenotype and highlight the importance of neuronal cell models to study the pathophysiology of CMT2Z., Instituto de Salud Carlos III (ISCIII) - Subdireccion General de Evaluacion y Fomento de la Investigacion within the framework of the National R+D+I Plan (PI15/00187 to C. E. and PI16/00403 to T. S.), co-funded with FEDER funds; Ramon Areces Foundation (CIVP17A2810 to C. E.); Generalitat Valenciana (PROMETEO/2018/135 to C. E. and T. S.); AFM-Telethon (21500 to C. E. and R. C.); National Health and Medical Research Council of Australia Grant (APP1046680 to M. K.); Czech Health Research Council (AZV16-30206A to P. L.); Swedish StratNeuro program grant; Swedish Research Council (2015-02394 to R. C.). C. E. had a 'Miguel Servet' contract funded by the ISCIII and the Centro de Investigacion Principe Felipe (CPII14/00002). P. S. is the recipient of a FPU-PhD fellowship funded by the Spanish Ministry of Education, Culture and Sport [FPU15/00964]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

The EGR2 gene is involved in axonal Charcot-Marie-Tooth disease

  • Sevilla, T.
  • Sivera, R.
  • Martínez-Rubio, D.
  • Lupo, V.
  • Chumillas, M.J.
  • Calpena-Corpas, E.
  • Dopazo, J.
  • Vílchez, J.J.
  • Palau, F.
  • Espinós-Armero, Carmen Ángeles
[EN] Background and purpose: A three-generation family affected by axonal Charcot-Marie-Tooth disease (CMT) was investigated with the aim of discovering genetic defects and to further characterize the phenotype. Methods: The clinical, nerve conduction studies and muscle magnetic resonance images of the patients were reviewed. A whole exome sequencing was performed and the changes were investigated by genetic studies, in silico analysis and luciferase reporter assays. Results: A novel c.1226G>A change (p.R409Q) in the EGR2 gene was identified. Patients presented with a typical, late-onset axonal CMT phenotype with variable severity that was confirmed in the ancillary tests. The in silico studies showed that the residue R409 is an evolutionary conserved amino acid. The p.R409Q mutation, which is predicted as probably damaging, would alter the conformation of the protein slightly and would cause a decrease of gene expression. Conclusions: This is the first report of an EGR2 mutation presenting as an axonal CMT phenotype with variable severity. This study broadens the phenotype of the EGR2-related neuropathies and suggests that the genetic testing of patients suffering from axonal CMT should include the EGR2 gene., This collaborative joint project is awarded by IRDiRC and funded by the Instituto de Salud Carlos III (ISCIII) - Subdireccion General de Evaluacion y Fomento de la Investigacion within the framework of the National R+D+I Plan (Grants IR11/TREAT-CMT, PI12/00946 and PI12/00453), co-funded with FEDER funds. C.E. has a "Miguel Servet' contract funded by the ISCIII and Centro de Investigacion Principe Felipe (CIPF) (Grant no. CPII14/00002). We are also grateful to Itziar Llopis for sample management.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders

  • Romero-Miguel, Diego
  • Casquero-Veiga, Marta
  • MacDowell, Karina S.
  • Torres Sánchez, Sonia
  • García Partida, José Antonio
  • Lamanna-Rama, Nicolás
  • Romero-Miranda, Ana
  • Berrocoso Domínguez, Esther María
  • Leza, Juan Carlos
  • Desco, Manuel
  • Soto-Montenegro, María Luisa
Background: Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model. Methods: On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35-49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue. Results: MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen). Conclusions: MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2-ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains., M.L.S. was supported by the Ministerio de Ciencia, Innovacion y Universidades, Instituto de Salud Carlos III (projects PI14/00860 and PI17/01766, and grant CPII14/00005), co-financed by European Regional Development Fund (ERDF), "A way of making Europe", CIBER of Mental Health (CIBERSAM), Delegacion del Gobierno para el Plan Nacional sobre Drogas (2017/085), Fundacion Mapfre and Fundacion Alicia Koplowitz. M.C.-V. was supported by Fundacion Tatiana Perez de Guzman el Bueno. D.R.-M. was supported by Consejeria de Educacion e Investigacion, Comunidad de Madrid, co-funded by European Social Fund "Investing in your future" (grant, PEJD-2018-PRE/BMD-7899). N.L.-R. was supported by Instituto de investigacion Sanitaria Gregorio Maranon. A.R.-M. was supported by Consejeria de Educacion e Investigacion, Comunidad de Madrid, co-funded by European Social Fund "Investing in your future" (grant, PEJ15/BIO/TL-0216). The CNIC was supported by the Spanish Ministerio de Ciencia, Innovacion y Universidades (MCIU) and the Pro-CNIC Foundation. J.C.L. was supported by the Spanish Ministry of Economy, Industry and Competitiveness (MINECOEU-FEDER) SAF2016-75500-R and CIBERSAM. E.B.D., S.T.-S., and J.A.G.-P. were supported by grants: co-financed by the "Fondo Europeo de Desarrollo Regional" (FEDER)-UE "A way to build Europe" from the "Ministerio de Economia y Competitividad" (MINECO: RTI2018-099778-B-I00) and the "Ministerio de SaludInstituto de Salud Carlos III (PI18/01691); from the "Plan Nacional sobre Drogas, Ministerio de Sanidad, Consumo y Bienestar Social" (2019I041); from the "Programa Operativo de Andalucia FEDER, Iniciativa Territorial Integrada ITI 2014-2020 Consejeria Salud, Junta de Andalucia" (PI-0080-2017 and PI-0009-2017); from the Consejeria de Salud de la Junta de Andalucia (PI-0134-2018); from the University of Cadiz (PR2019-046); from the "Instituto de Investigacion e Innovacion en Ciencias Biomedicas de Cadiz-INiBICA" (IN-C22; LI19/06IN-CO22); from the "Consejeria de Economia, Innovacion, Ciencia y Empleo de la Junta de Andalucia" (CTS-510); from the "CIBERSAM" (CB/07/09/0033).
Docta Complutense
Publicación Artículo científico (JournalArticle)

Early Preventive Treatment With Enalapril Improves Cardiac Function and Delays Mortality in Mice With Arrhythmogenic Right Ventricular Cardiomyopathy Type 5

  • Domínguez, Fernando
  • Lalaguna, Laura
  • López-Olañeta, Marina
  • Padrón-Barthe, Laura
  • Román, Marta
  • Bello-Arroyo, Elísabet
  • Briceño, Ana
  • Gonzalez-Lopez, Esther
  • Segovia-Cubero, Javier
  • García-Pavía, Pablo
  • Lara-Pezzi, Enrique
  • Villalba Orero, María
Background: Arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5) is an inherited cardiac disease with complete penetrance and an aggressive clinical course caused by mutations in TMEM43 (transmembrane protein 43). There is no cure for ARVC5 and palliative treatment is started once the phenotype is present. A transgenic mouse model of ARVC5 expressing human TMEM43-S358L (TMEM43mut) recapitulates the human disease, enabling the exploration of preventive treatments. The aim of this study is to determine whether preventive treatment with heart failure drugs (β-blockers, ACE [angiotensin-converting enzyme] inhibitors, mineralocorticoid-receptor antagonists) improves the disease course of ARVC5 in TMEM43mut mice. Methods: TMEM43mut male/female mice were treated with metoprolol (β-blockers), enalapril (ACE inhibitor), spironolactone (mineralocorticoid-receptor antagonist), ACE inhibitor + mineralocorticoid-receptor antagonist, ACE inhibitor + mineralocorticoid-receptor antagonist + β-blockers or left untreated. Drugs were initiated at 3 weeks of age, before ARVC5 phenotype, and serial ECG and echocardiograms were performed. Results: TMEM43mut mice treated with enalapril showed a significantly increased median survival compared with untreated mice (26 versus 21 weeks; P=0.003). Enalapril-treated mice also exhibited increased left ventricular ejection fraction at 4 months compared with controls (37.0% versus 24.9%; P=0.004), shorter QRS duration and reduced left ventricle fibrosis. Combined regimens including enalapril also showed positive effects. Metoprolol decreased QRS voltage prematurely and resulted in a nonsignificant decrease in left ventricular ejection fraction compared with untreated TMEM43mut mice. Conclusions: Preventive enalapril-based regimens reduced fibrosis, improved ECG, echocardiographic parameters and survival of ARVC5 mice. Early metoprolol did not show positive effects and caused premature ECG abnormalities. Our findings pave the way to consider prophylactic enalapril in asymptomatic ARVC5 genetic carriers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low doses of LPS exacerbate the inflammatory response and trigger death on TLR3-primed human monocytes

  • Monguió-Tortajada, Marta|||0000-0003-2125-0810
  • Franquesa, Marcella|||0000-0002-1287-8908
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
TLR sensing of pathogens triggers monocyte activation to initiate the host innate immune response to infection. Monocytes can dynamically adapt to different TLR agonists inducing different patterns of inflammatory response, and the sequence of exposure to TLRs can dramatically modulate cell activation. Understanding the interactions between TLR signalling that lead to synergy, priming and tolerance to TLR agonists may help explain how prior infections and inflammatory conditioning can regulate the innate immune response to subsequent infections. Our goal was to investigate the role of MyD88-independent/dependent TLR priming on modulating the monocyte response to LPS exposure. We stimulated human blood monocytes with agonists for TLR4 (LPS), TLR3 (poly(I:C)) and TLR7/8 (R848) and subsequently challenged them to low doses of endotoxin. The different TLR agonists promoted distinct inflammatory signatures in monocytes. Upon subsequent LPS challenge, LPS- and R848-primed monocytes did not enhance the previous response, whereas poly(I:C)-primed monocytes exhibited a significant inflammatory response concomitant with a sharp reduction on cell viability. Our results show that TLR3-primed monocytes are prompted to cell death by apoptosis in the presence of low endotoxin levels, concurrent with the production of high levels of TNFα and IL6. Of note, blocking of TNFR I/II in those monocytes did reduce TNFα production but did not abrogate cell death. Instead, direct signalling through TLR4 was responsible of such effect. Collectively, our study provides new insights on the effects of cross-priming and synergism between TLR3 and TLR4, identifying the selective induction of apoptosis as a strategy for TLR-mediated host innate response.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism

  • Matalonga, Jonathan
  • Glaria, Estibaliz
  • Bresque, Mariana|||0000-0002-4570-3629
  • Escande, Carlos|||0000-0002-9611-0903
  • Carbó, José María|||0000-0001-8301-5360
  • Kiefer, Kerstin
  • Vicente, Ruben
  • León, Theresa E.
  • Beceiro, Susana
  • Pascual-García, Mónica|||0000-0002-9768-0641
  • Serret, Joan
  • Sanjurjo, Lucía|||0000-0003-4006-8010
  • Morón-Ros, Samantha|||0000-0002-6205-2442
  • Riera, Antoni|||0000-0001-7142-7675
  • Paytubi, Sonia
  • Antonio Juarez, Antonio
  • Sotillo, Fernando
  • Lindbom, Lennart
  • Caelles, Carme
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Sancho, Jaime
  • Castrillo, Antonio|||0000-0002-2057-2159
  • Chini, Eduardo N.
  • Valledor, Annabel F.|||0000-0003-4232-2633
Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of nonopsonized Salmonella to infect macrophages.remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bonemarrow- derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Matito, Judit|||0000-0001-7560-7737
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Navarro, Alejandro|||0000-0001-5903-270X
  • Cedrés, Susana|||0000-0002-0648-7978
  • Pardo Aranda, Nuria
  • Martinez de Castro, Ana
  • Remon, Jordin
  • Miquel, J. M.
  • Guillaumet-Adkins, A.
  • Nadal, Ernest|||0000-0002-9674-5554
  • Rodriguez Esteban, Gustavo
  • Arqués Casamitjana, Oriol
  • Fasani, Roberta|||0000-0003-1630-9988
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Heyn, Holger|||0000-0002-3276-1889
  • Villanueva Garatachea, Alberto
  • Palmer, Héctor G.
  • Vivancos, Ana|||0000-0003-2888-6512
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. Different mechanisms of acquired resistance to third-generation EGFR-TKIs have been proposed. It is therefore crucial to identify new and effective strategies to overcome successive acquired mechanisms of resistance. For Amplicon-seq analysis, samples from the index patient (primary and metastasis lesions at different timepoints) as well as the patient-derived orthotopic xenograft tumors corresponding to the different treatment arms were used. All samples were formalin-fixed paraffin-embedded, selected and evaluated by a pathologist. For droplet digital PCR, 20 patients diagnosed with NSCLC at baseline or progression to different lines of TKI therapies were selected. Formalin-fixed paraffin-embedded blocks corresponding to either primary tumor or metastasis specimens were used for analysis. For single-cell analysis, orthotopically grown metastases were dissected from the brain of an athymic nu/nu mouse and cryopreserved at -80°C. In a brain metastasis lesion from a NSCLC patient presenting an EGFR T790M mutation, we detected MET gene amplification after prolonged treatment with osimertinib. Importantly, the combination of capmatinib (c-MET inhibitor) and afatinib (ErbB-1/2/4 inhibitor) completely suppressed tumor growth in mice orthotopically injected with cells derived from this brain metastasis. In those mice treated with capmatinib or afatinib as monotherapy, we observed the emergence of KRAS G12C clones. Single-cell gene expression analyses also revealed intratumor heterogeneity, indicating the presence of a KRAS -driven subclone. We also detected low-frequent KRAS G12C alleles in patients treated with various EGFR-TKIs. Acquired resistance to subsequent EGFR-TKI treatment lines in EGFR -mutant lung cancer patients may induce genetic plasticity. We assess the biological insights of tumor heterogeneity in an osimertinib-resistant tumor with acquired MET- amplification and propose new treatment strategies in this situation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Perrault syndrome with neurological features in a compound heterozygote for two TWNK mutations, Overlap of TWNK-related recessive disorders

  • Domínguez-Ruiz, María
  • García-Martínez, Alberto
  • Corral-Juan, Marc|||0000-0001-9407-7516
  • Pérez-Álvarez, Ángel I.
  • Plasencia, Ana M.
  • Villamar, Manuela
  • Moreno-Pelayo, Miguel Ángel|||0000-0003-3839-5098
  • Matilla-Dueñas, Antoni|||0000-0002-3514-4181
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Del Castillo, Ignacio
Background: Perrault syndrome is a rare autosomal recessive disorder that is characterized by the association of sensorineural hearing impairment and ovarian dysgenesis in females, whereas males have only hearing impairment. In some cases, patients present with a diversity of neurological signs. To date, mutations in six genes are known to cause Perrault syndrome, but they do not explain all clinically-diagnosed cases. In addition, the number of reported cases and the spectra of mutations are still small to establish conclusive genotype-phenotype correlations. Methods: Affected siblings from family SH19, who presented with features that were suggestive of Perrault syndrome, were subjected to audiological, neurological and gynecological examination. The genetic study included genotyping and haplotype analysis for microsatellite markers close to the genes involved in Perrault syndrome, whole-exome sequencing, and Sanger sequencing of the coding region of the TWNK gene. Results: Three siblings from family SH19 shared similar clinical features: childhood-onset bilateral sensorineural hearing impairment, which progressed to profound deafness in the second decade of life; neurological signs (spinocerebellar ataxia, polyneuropathy), with onset in the fourth decade of life in the two females and at age 20 years in the male; gonadal dysfunction with early cessation of menses in the two females. The genetic study revealed two compound heterozygous pathogenic mutations in the TWNK gene in the three affected subjects: c.85C.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Torrens, Laura
  • Simón-Coma, Marina
  • Royo, Laura|||0000-0001-5770-2001
  • Domingo-Sàbat, Montse|||0000-0001-6687-3259
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Akers, Nicholas
  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Ragull, Sonia
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Villalmanzo, Núria
  • Cairo, Stefano
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Kappler, Roland
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Guerra Pastrian, Laura|||0000-0002-8478-8522
  • Sábado, Constantino|||0000-0003-3956-5466
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Piñeyro, David|||0000-0001-5633-3339
  • Vázquez-Vitali, María
  • Kuchuk, Olga
  • Mateos, María Elena
  • Ramírez, Gema
  • López Santamaría, Manuel
  • Mozo, Yasmina
  • Soriano, Aroa|||0000-0001-9659-1471
  • Grotzer, Michael
  • Branchereau, Sophie
  • García de Andoin, Nagore
  • López-Ibor, Blanca
  • López-Almaraz, Ricardo
  • Salinas, José Antonio
  • Torres, Bárbara
  • Hernández, Francisco
  • Uriz, José Javier
  • Fabre, Monique
  • Blanco, Julià|||0000-0002-2225-0217
  • Paris, Claudia
  • Bajčiová, Viera
  • Laureys, Geneviève
  • Masnou, Helena|||0000-0003-0632-1393
  • Clos, Ariadna|||0000-0002-6414-2097
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Guettier, Catherine
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Planas, Ramón
  • Jordà, Mireia|||0000-0003-3709-1850
  • Nonell, Lara|||0000-0002-8538-8213
  • Czauderna, Piotr
  • Morland, Bruce
  • Sia, Daniela|||0000-0002-9000-611X
  • Losic, Bojan
  • Buendia, Marie Annick
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Armengol, Carolina|||0000-0002-4690-4027
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. Methods: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically annotated samples from 113 patients with HB, using high-throughput technologies. Results: We discovered a widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified 2 epigenomic clusters (Epi-CA, Epi-CB) with distinct degrees of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first molecular risk stratification of HB (MRS-HB), which encompasses 3 main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs, as its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth. Conclusions: These findings provide a detailed insight into the molecular features of HB and could be used to improve current clinical stratification approaches and to develop treatments for patients with HB. Lay summary: Hepatoblastoma is a rare childhood liver cancer that has been understudied. We have used cutting-edge technologies to expand our molecular knowledge of this cancer. Our biological findings can be used to improve clinical management and pave the way for the development of novel therapies for this cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Beneficial Effect of Low-Dose Aspirin in a Murine Model of Active Tuberculosis

  • Kroesen, Vera Marie
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • García, Eric
  • Rosales, Yaiza
  • Díaz, Jorge
  • Martín-Céspedes, Montse
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vilaplana, Cristina|||0000-0002-2808-7270
An excessive, non-productive host-immune response is detrimental in active, chronic tuberculosis (TB) disease as it typically leads to tissue damage. Given their anti-inflammatory effect, non-steroidal anti-inflammatory drugs can potentially attenuate excessive inflammation in active TB disease. As such, we investigated the prophylactic and therapeutic effect of low-dose aspirin (LDA) (3 mg/kg/day), either alone or in combination with common anti-TB treatment or BCG vaccination, on disease outcome in an experimental murine model of active TB. Survival rate, bacillary load (BL) in lungs, and lung pathology were measured. The possible mechanism of action of LDA on the host's immune response was also evaluated by measuring levels of CD5L/AIM, selected cytokines/chemokines and other inflammatory markers in serum and lung tissue. LDA increased survival, had anti-inflammatory effects, reduced lung pathology, and decreased bacillary load in late-stage TB disease. Moreover, in combination with common anti-TB treatment, LDA enhanced survival and reduced lung pathology. Results from the immunological studies suggest the anti-inflammatory action of LDA at both a local and a systemic level. Our results showed a systemic decrease in neutrophilic recruitment, decreased levels of acute-phase reaction cytokines (IL-6, IL-1β, and TNF-α) at late stage and a delay in the decrease in T cell response (in terms of IFN-γ, IL-2, and IL-10 serum levels) that occurs during the course of Mycobacterium tuberculosis infection. An anti-inflammatory milieu was detected in the lung, with less neutrophil recruitment and lower levels of tissue factor. In conclusion, LDA may be beneficial as an adjunct to standard anti-TB treatment in the later stage of active TB by reducing excess, non-productive inflammation, while enhancing Th1-cell responses for elimination of the bacilli.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain

  • Sivera, Rafael|||0000-0003-2810-1180
  • Frasquet, Marina
  • Lupo, Vincenzo|||0000-0002-3774-9854
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Blanco-Arias, Patricia
  • Pardo, Julio|||0000-0001-8807-1310
  • Fernández-Torrón, Roberto
  • de Munain, Adolfo López
  • Márquez-Infante, Celedonio
  • Villarreal, Liliana
  • Carbonell, Pilar
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Segovia, Sonia
  • Illa, Isabel|||0000-0002-2186-2684
  • Frongia, Anna Lia
  • Nascimento, Andrés
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • García-Romero, María del Mar
  • Pascual, Samuel Ignacio
  • Pelayo-Negro, Ana Lara
  • Berciano, José|||0000-0001-9261-9748
  • Guerrero, Antonio
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Camacho, Ana
  • Esteban-Pérez, Jesús
  • Chumillas, María José
  • Barreiro, Marisa
  • Díaz, Carmen
  • Palau, Francesc|||0000-0002-8635-5421
  • Vílchez, Juan J.|||0000-0002-0532-2872
  • Espinós, Carmen|||0000-0003-4435-1809
  • Sevilla, Teresa|||0000-0003-4716-2667
Mutations in the GDAP1 gene can cause Charcot-Marie-Tooth disease. These mutations are quite rare in most Western countries but not so in certain regions of Spain or other Mediterranean countries. This cross-sectional retrospective multicenter study analyzed the clinical and genetic characteristics of patients with GDAP1 mutations across Spain. 99 patients were identified, which were distributed across most of Spain, but especially in the Northwest and Mediterranean regions. The most common genotypes were p.R120W (in 81% of patients with autosomal dominant inheritance) and p.Q163X (in 73% of autosomal recessive patients). Patients with recessively inherited mutations had a more severe phenotype, and certain clinical features, like dysphonia or respiratory dysfunction, were exclusively detected in this group. Dominantly inherited mutations had prominent clinical variability regarding severity, including 29% of patients who were asymptomatic. There were minor clinical differences between patients harboring specific mutations but not when grouped according to localization or type of mutation. This is the largest clinical series to date of patients with GDAP1 mutations, and it contributes to define the genetic distribution and genotype-phenotype correlation in this rare form of CMT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Contribution of Elevated Glucose and Oxidized LDL to Macrophage Inflammation, A Role for PRAS40/Akt-Dependent Shedding of Soluble CD14

  • Sanjurjo, Lucía|||0000-0003-4006-8010
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Villalmanzo, Núria
  • Téllez, Érica|||0000-0003-1034-6307
  • Ramírez-Morros, Anna|||0000-0001-8263-1292
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Mauricio, Didac|||0000-0002-2868-0250
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
Atherosclerosis, a process in which macrophages play a key role, is accelerated in diabetes. Elevated concentrations of serum-oxidized low-density lipoproteins (oxLDL) represent a common feature of both conditions. The main goal of this study was to determine the contribution of oxLDL to the inflammatory response of macrophages exposed to diabetic-mimicking conditions. THP1 cells and peripheral blood monocytes purified from non-diabetic healthy donors were cultured under normal (5 mM) or high glucose (HG) (15 mM) with oxLDL. Then, foam cell formation, expression of CD80, HLADR, CD23, CD206, and CD163, as well as toll-like receptor 4 (TLR4) and co-receptors CD36 and CD14 (both at the cell surface and soluble (sCD14)), and inflammatory mediators' production were measured by flow cytometry, RT-qPCR, or ELISA. Additionally, serum sCD14 was determined in subjects with subclinical atherosclerosis with and without diabetes by ELISA. Our results showed that oxLDL-mediated intracellular lipid accumulation via CD36 increased under HG and that HG + oxLDL enhanced TNF, IL1B, and IL8, and decreased IL10. Moreover, TLR4 was upregulated in macrophages under HG and monocytes of subjects with diabetes and atherosclerosis. Interestingly, HG-oxLDL upregulated CD14 gene expression, although its total cellular protein abundance remained unaltered. sCD14 shedding via PRAS40/Akt-dependent mechanisms, with pro-inflammatory activity, was significantly increased in cultured macrophages and plasma from subjects with diabetes and subclinical atherosclerosis or hypercholesterolemia. Our data support an enhanced synergistic pro-inflammatory effect induced by HG and oxLDL in cultured human macrophages, possibly explained by increased sCD14 shedding.